NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Beta Bionics, Inc. (BBNX) Stock Analysis

Beta Bionics, Inc. (BBNX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BBNX

$18.40

+$0.66 (+3.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BBNX with… →

BBNX Key Statistics

As of Oct 21, 2026
Trading
Open
$17.79
Previous Close
$17.74
Day's Range
17.17–18.49
52-Week Range
8.80–32.71
Volume
1.44M
Valuation
Market Cap
$882.02M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.64
Financials (FY)
Revenue (FY)
$100.25M+53.94%
Net Income (FY)
−$73.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
−61.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.95M
1-Year Return
−12.30%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
1.29M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BBNX closed at $18.40, −12.30% over 1 year.

Beta Bionics, Inc. (BBNX) has a market capitalization of $882.02M.

In fiscal 2025, BBNX reported revenue of $100.25M.

BBNX Stock Return by Calendar Year

Beta Bionics, Inc. (BBNX) return since Jan 2025: what $10,000 became

1 year
$10,000 $8,770
−12.30%
Since Jan 2025
$10,000 $7,787
−22.13%

If you had invested $10,000 in Beta Bionics, Inc. (BBNX) at the close on January 30, 2025, the earliest close on record here, it would have been worth $7,787 at the close on October 21, 2026: −22.13% in total, −13.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.61%
2025+28.95%

As of October 21, 2026.

BBNX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$100.25M−$73.20M−73.0%
2024$65.12M−$54.76M−84.1%
2023$12.00M−$44.10M−367.6%
2022$179.00K−$64.75M−36,173.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$100.25M$55.54M−$71.68M−$73.20M−73.0%
2024$65.12M$35.89M−$45.25M−$54.76M−84.1%
2023$12.00M$6.31M−$35.85M−$44.10M−367.6%
2022$179.00K$179.00K−$65.84M−$64.75M−36,173.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BBNX Valuation vs Medical Devices Median

Median of 145 stocks
MetricBBNXMedical Devices medianvs median
P/S ratio7.412.53193% above
Profit margin−61.32%−14.78%46.5 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Beta Bionics, Inc. (BBNX) at $882.02M. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 420 employees.

Over the past 52 weeks the price has ranged from $8.80 to $32.71. BBNX last closed at $18.40 on October 21, 2026. That is +$0.66 (+3.72%) against the previous close. The latest close sits 109.09% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $100.25M. That is +53.94% against the prior fiscal year, when revenue was $65.12M. The same year closed with a net loss of $73.20M. Profit margin runs at −61.32%. That is 46.5 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −1.64.

Across the 4 fiscal years on file, revenue moves from $179.00K in 2022 to $100.25M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 7.41. On price-to-sales that is 192.96% above the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −12.30%. The stored price history starts on January 30, 2025, and the total return since then is −22.13%. Daily returns over the trailing 1 year annualize to a volatility of 82.66%.

Growth & Income

No dividend is on file for BBNX.

The record holds one complete calendar year, 2025, which returned +28.95%. So far in 2026 the total return is −39.61%.

Peer Comparison

Beta Bionics, Inc. (BBNX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Beta Bionics, Inc. BBNX $882.02M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Beta Bionics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Beta Bionics, Inc.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Visit website →